Pharmaceutical brands carry a heavy load of assumed knowledge. The people who have worked on a product for a few years know the disease, the patient journey, the label, the competitors, the payers, the history of the brand and dozens of acronyms. They use all of it in every meeting without explaining it.
A new brand manager, sales leader or access manager has to absorb that knowledge before they can contribute, and most companies leave them to do it from old slide decks, shared drives and kind colleagues. It usually takes months. In the meantime they nod along in meetings, ask questions they suspect they should already know the answers to, and make decisions with half the picture.
A brand primer fixes this. It is not a new idea, but it is rarely done well, and even more rarely kept current. This guide covers what a good one contains, how to keep it alive, and how to use it in a new joiner’s first week.
Why onboarding onto a pharma brand takes so long
The knowledge needed to work on a brand comes from several functions, and no single person holds all of it.
- Medical knows the disease, the evidence and the experts.
- Market access knows the payers, the coverage and the pricing history.
- Analytics knows the numbers, how they are calculated and where they come from.
- Competitive intelligence knows the competitors and what is coming.
- Regulatory knows the label, the exclusivity timeline and the commitments.
- Sales knows the customers and what really happens in the field.
A new team member has to visit all of them. Each conversation is useful, but each is shaped by what that function cares about, and nobody tells the new joiner how the pieces fit together. The primer is where they fit.
What a good brand primer covers
The structure below works for most brands. Adjust it for your product, but think hard before dropping a section entirely.
| Section | What to include | Who usually owns it |
|---|---|---|
| The brand on a page | What the product is, who it is for, why it matters, how it is doing, what is coming | Brand lead |
| The disease and the patient | Epidemiology, how patients present, diagnosis, the patient journey, unmet need | Medical |
| The treatment landscape | Current guidelines, lines of therapy, how clinicians actually treat | Medical |
| The product | Mechanism, approved indications, dosing and administration, key safety information | Medical and regulatory |
| The evidence | Pivotal trials and their results, key secondary data, real-world evidence, gaps | Medical |
| The competition | Competitor matrix, positioning, pipeline, upcoming catalysts | Competitive intelligence |
| Access and pricing | Coverage by major payer, utilization management, list price and gross-to-net, HTA outcomes | Market access |
| Performance | The KPIs the team uses, how each is defined, current trends | Analytics |
| Customers | Prescriber segments, key accounts, specialty pharmacies and hubs, patient support | Sales and marketing |
| Regulatory and lifecycle | Approval history, label changes, exclusivity and patents, post-marketing commitments | Regulatory |
| Vocabulary | Every acronym and term the team uses, defined | Brand team |
| The team | Who does what, governance, the planning calendar, where documents live | Brand lead |
The sections that follow explain what makes each one useful.
The brand on a page
Start with a single page that a new joiner can read in five minutes. What is the product, who is it for, why does it matter, how is it performing, and what are the two or three biggest things happening this year? If the reader understands nothing else, they should understand this.
The disease and the patient
Explain the condition the way a well-informed non-clinician would want it explained. How common it is, who gets it, how it is diagnosed, how long patients typically wait for a diagnosis, what happens to them over time, and what they and their caregivers find hardest. Include the patient journey from first symptom to treatment, and mark where patients are lost along the way. This section is often the one new joiners say they valued most.
The treatment landscape
Summarize the current treatment guidelines and how clinicians actually follow them, which are not always the same thing. Lay out the lines of therapy and where your product sits. Note any recent or expected guideline changes.
The product
Mechanism of action, approved indications, dosing and administration, and the key safety information. Anchor this section to the approved label, and link to the full prescribing information rather than paraphrasing it. If the product has different labels in different markets, say so plainly.
The evidence
The pivotal trials, what they showed, and how the results are usually described. Include the important secondary analyses, any real-world evidence, and the open questions: what the evidence does not yet answer, and what is being done about it. Medical should own this section and decide how it is phrased.
The competition
A competitor matrix with your product and its main competitors side by side, the positioning of each, the pipeline behind them, and a catalyst calendar of upcoming events. Our competitor matrix template is a reasonable starting point. This section goes out of date faster than any other.
Access and pricing
Coverage position with the payers that matter most, the utilization management attached (such as prior authorization and step therapy), the list price history and how net price compares, and health technology assessment outcomes outside the US. New joiners from outside the industry often find this section the hardest, so err on the side of explaining.
Performance
The handful of metrics the team uses to judge how the brand is doing, with a definition for each. Do not assume a new joiner knows the difference between NBRx and NRx, or which data source the team trusts for share. Our guide to KPI definitions covers the common ones and why teams disagree about them.
Customers
Who prescribes the product, how they are segmented, the key accounts and institutions, the specialty pharmacies and hubs involved, and what patient support is available. This is where the field perspective belongs.
Regulatory and lifecycle
Approval history, past label changes, post-marketing commitments, and the exclusivity and patent timeline. The date of loss of exclusivity shapes almost every long-term decision, and new joiners should know it.
Vocabulary
Every acronym, abbreviation and in-house term the team uses, defined in a sentence. This is the easiest section to write and one of the most appreciated. Our glossary covers the industry-wide terms. Your primer should add the ones specific to your brand and company.
The team
Who does what, how decisions are made, when the planning cycle runs, which meetings matter, and where the important documents live.
Keeping the primer current
Most brand primers are written once, during a launch or a reorganization, and then slowly rot. Six months later, half of it is wrong and nobody trusts the rest. A few practices prevent this.
Give every section an owner. The brand lead owns the whole, but each section should be maintained by the function that knows it best. Write the owner’s name at the top of the section.
Show the date. Put a “last reviewed” date on every section. Readers then know how much to trust it, and owners can see when theirs is overdue.
Review on a schedule and on events. A quarterly review keeps the primer from drifting. Certain events should trigger an immediate update: a label change, a competitor approval, a significant coverage decision, a guideline update, a change in the team.
Keep detail elsewhere. The primer should explain and orient. Detailed data, full trial reports and complete payer lists belong in linked documents. A primer that tries to contain everything becomes impossible to maintain.
Ask new joiners. At the end of their first month, ask each new team member what was missing, wrong or confusing. They are the only readers who see the primer with fresh eyes.
A first-week plan for a new team member
The primer is most useful as part of a structured first week. The plan below is a starting point.
Day 1: the brand on a page and the disease. Read the summary and the disease section. Meet the brand lead. Write down every term you do not understand, and look each one up.
Day 2: the treatment landscape, the product and the evidence. Read those sections. Spend an hour with a medical colleague going through the evidence and asking the questions you wrote down.
Day 3: the competition. Read the competitive section and the catalyst calendar. Spend time with the CI lead on what is coming in the next twelve months and which events worry the team most.
Day 4: access and performance. Read the access and performance sections. Spend time with the access lead and with analytics, and ask how each key metric is calculated.
Day 5: customers and the team. Read the remaining sections. If possible, spend part of the day with a field colleague. End the week by writing a one-page summary of the brand in your own words, and review it with your manager.
By the end of the week, a new joiner will not know everything, but they will know how the pieces fit, who to ask about what, and enough of the vocabulary to follow the conversation.
Compliance considerations
A brand primer is an internal document, but it still needs care.
- Anchor product claims to the label. Describe the product’s indications, efficacy and safety the way the approved label does. Off-label information has no place in a commercial training document.
- Respect the medical boundary. Let medical own and phrase the evidence and disease sections. Commercial teams should not reinterpret clinical data.
- Review before wider use. If the primer is used to train field teams or shared beyond the brand team, it will usually need to go through the same medical, legal and regulatory review as other training materials.
- Handle confidential material carefully. Contract terms, rebate levels and internal forecasts may need to sit in a restricted appendix rather than in the main document.
Common mistakes
Building it from old decks. Copying slides from the last brand plan produces a primer that is out of date on day one and full of internal shorthand.
Writing for the experts. The primer is for someone new. If a section assumes knowledge, it fails its purpose.
One author, no owners. A primer written by one person becomes stale when that person moves on.
No dates. Without a “last reviewed” date on each section, readers cannot tell which parts to trust.
Burying the summary. The single-page overview is the most read section. Put it first and keep it current.
When the document stops being enough
A primer kept in a document works well for a single brand with a stable team. It starts to strain when the competitive and access picture changes every week, when several brands need the same treatment, or when nobody has time to keep the sections current. At that point the most volatile sections, especially the competition, access and performance, are better maintained continuously from their sources than updated by hand each quarter. That is the work Pharma Landscape 360 is designed to take over, while the brand team keeps owning the judgment.
Further reading
- Our guide to pharma competitive intelligence explains how to build and maintain the competitive section.
- Our guide to KPI definitions covers the performance metrics most brand teams use and how to define them.
- The glossary is a ready-made vocabulary section for industry-wide terms.